Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Clinical Trial Nuedexta in Subjects With ALS

Study:

The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)

Rationale:

n/a

Purpose:

The purpose of this study is to determine whether Nuedexta is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control)associated with Amyotrophic Lateral Sclerosis (ALS).

Study Status: Recruiting

Recruiting:
Nicole Berry 216-445-1741 berryn@ccf.org

Condition Intervention Phase
Amyotrophic Lateral Sclerosis (ALS) Drug: Nuedexta
Drug: Matching Placebo
Phase 2

Verified by Center for Neurologic Study, La Jolla, California, December, 2013

Sponsored by: Center for Neurologic Study, La Jolla, California,
Information provided by: Center for Neurologic Study, La Jolla, California,
ClinicalTrials.gov identifier: NCT01806857

Study Type: Interventional

Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

The Cleveland Clinic
Cleveland, Ohio 44195
United States

Richard A Smith, MD., Principal Investigator
Jeremy Shefner, MD, PhD., Principal Investigator
Merit E Cudkowicz, MD, MSc., Principal Investigator

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.

Cleveland Clinic Mobile Site